SHANG.FOS.PHARM.GR.H YC 1 (08HH) - Total Liabilities
Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) has total liabilities worth €59.30 Billion EUR (≈ $69.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 08HH year-over-year net asset growth to track the company's year-over-year net asset growth rate.
SHANG.FOS.PHARM.GR.H YC 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's total liabilities have evolved over time, based on quarterly financial data.
SHANG.FOS.PHARM.GR.H YC 1 Competitors by Total Liabilities
The table below lists competitors of SHANG.FOS.PHARM.GR.H YC 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hankuk Carbon
KO:017960
|
Korea | ₩408.25 Billion |
|
Shinva Medical Instrument Co Ltd
SHG:600587
|
China | CN¥6.91 Billion |
|
MasterBrand Inc.
NYSE:MBC
|
USA | $1.76 Billion |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
China | CN¥133.17 Million |
|
Edan Instruments Inc
SHE:300206
|
China | CN¥361.67 Million |
|
Temple Bar Investment Trust
LSE:TMPL
|
UK | £76.82 Million |
|
Hotai Finance Corp
TW:6592
|
Taiwan | NT$286.19 Billion |
|
TripAdvisor Inc
NASDAQ:TRIP
|
USA | $2.10 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANG.FOS.PHARM.GR.H YC 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 08HH market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANG.FOS.PHARM.GR.H YC 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below shows the annual total liabilities of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €58.21 Billion ≈ $68.06 Billion |
+1.19% |
| 2024-12-31 | €57.53 Billion ≈ $67.25 Billion |
+1.18% |
| 2023-12-31 | €56.85 Billion ≈ $66.47 Billion |
+7.16% |
| 2022-12-31 | €53.05 Billion ≈ $62.03 Billion |
+18.09% |
| 2021-12-31 | €44.93 Billion ≈ $52.52 Billion |
-- |
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more